Openbookopenbook
Equity
Bio-Rad Laboratories Inc(BIO)
USD --+0.00%
Reward61Moderate
Risk35Moderate
📊75%Data
Strong 29% profit margin
BIO
+0.0 · +0.00%
USD · NYSE
Bio-Rad Laboratories Inc | Healthcare
Quality Compounder
Market Cap:7.43Bn
ℹ️
Reward Rating
61
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
35
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on BIO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $302.50.

What is Bio-Rad Laboratories Inc?

develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

BIO · Verdict

Solid reward · moderate risk

BIO scores well on cash flow and valuation with no major weaknesses flagged in the model.

Based on 88% data coverage

BIO · Verdict

What’s working & what to watch

Strengths 3

  • Cash flow81/100

    15% free-cash-flow margin

  • Valuation70/100

    P/E 27.5× · PEG 1.19

  • Profitability69/100

    29% net margin · 11% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Bio-Rad Laboratories Inc?

develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 7.43B, and a P/E ratio of 9.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (61)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap7.43B
P/E Ratio9.8797
Dividend YieldN/A
52 Week High343.12
52 Week Low211.43
Last AnnualDecember
IPO Date1/1/1966
IncorporatedUSA
Shares Outstanding22M
No. of Employees7,450
IndustryMedical Devices
ExchangeNYSE
Beta1.158
CurrencyUSD
Websitewww.bio-rad.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.